155 related articles for article (PubMed ID: 29720561)
1. Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer.
Ide H; Inoue S; Mizushima T; Jiang G; Chuang KH; Oya M; Miyamoto H
Mol Cancer Ther; 2018 Jul; 17(7):1566-1574. PubMed ID: 29720561
[TBL] [Abstract][Full Text] [Related]
2. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
[TBL] [Abstract][Full Text] [Related]
3. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
[TBL] [Abstract][Full Text] [Related]
4. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
[TBL] [Abstract][Full Text] [Related]
5. GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
Elahi Najafi MA; Yasui M; Teramoto Y; Tatenuma T; Jiang G; Miyamoto H
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762034
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis.
Izumi K; Zheng Y; Hsu JW; Chang C; Miyamoto H
Mol Carcinog; 2013 Feb; 52(2):94-102. PubMed ID: 22086872
[TBL] [Abstract][Full Text] [Related]
7. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor.
Izumi K; Zheng Y; Li Y; Zaengle J; Miyamoto H
Int J Oncol; 2012 Nov; 41(5):1587-92. PubMed ID: 22922989
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
Shang Z; Li Y; Zhang M; Tian J; Han R; Shyr CR; Messing E; Yeh S; Niu Y; Chang C
Mol Cancer Ther; 2015 Nov; 14(11):2586-94. PubMed ID: 26264279
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
[TBL] [Abstract][Full Text] [Related]
11. Androgen activates β-catenin signaling in bladder cancer cells.
Li Y; Zheng Y; Izumi K; Ishiguro H; Ye B; Li F; Miyamoto H
Endocr Relat Cancer; 2013 Jun; 20(3):293-304. PubMed ID: 23447569
[TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis.
Mizushima T; Jiang G; Kawahara T; Li P; Han B; Inoue S; Ide H; Kato I; Jalalizadeh M; Miyagi E; Fukuda M; Reis LO; Miyamoto H
Mol Cancer Ther; 2020 Sep; 19(9):1930-1942. PubMed ID: 32737155
[TBL] [Abstract][Full Text] [Related]
13. Androgens induce divergent proliferative responses in human breast cancer cell lines.
Birrell SN; Bentel JM; Hickey TE; Ricciardelli C; Weger MA; Horsfall DJ; Tilley WD
J Steroid Biochem Mol Biol; 1995 May; 52(5):459-67. PubMed ID: 7748811
[TBL] [Abstract][Full Text] [Related]
14. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
[TBL] [Abstract][Full Text] [Related]
15. Promotion of bladder cancer development and progression by androgen receptor signals.
Miyamoto H; Yang Z; Chen YT; Ishiguro H; Uemura H; Kubota Y; Nagashima Y; Chang YJ; Hu YC; Tsai MY; Yeh S; Messing EM; Chang C
J Natl Cancer Inst; 2007 Apr; 99(7):558-68. PubMed ID: 17406000
[TBL] [Abstract][Full Text] [Related]
16. Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.
Hedayati M; Haffner MC; Coulter JB; Raval RR; Zhang Y; Zhou H; Mian O; Knight EJ; Razavi N; Dalrymple S; Isaacs JT; Santos A; Hales R; Nelson WG; Yegnasubramanian S; DeWeese TL
Clin Cancer Res; 2016 Jul; 22(13):3310-3319. PubMed ID: 26831716
[TBL] [Abstract][Full Text] [Related]
17. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity.
Rath BH; Waung I; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2018 May; 17(5):1070-1078. PubMed ID: 29483212
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.
Marampon F; Gravina G; Ju X; Vetuschi A; Sferra R; Casimiro M; Pompili S; Festuccia C; Colapietro A; Gaudio E; Di Cesare E; Tombolini V; Pestell RG
Oncotarget; 2016 Feb; 7(5):5383-400. PubMed ID: 26689991
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling.
Inoue S; Ide H; Mizushima T; Jiang G; Netto GJ; Gotoh M; Miyamoto H
Mol Cancer Ther; 2018 Jun; 17(6):1303-1314. PubMed ID: 29592878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]